Study of Emactuzumab for Tenosynovial Giant Cell Tumor (TGCT)

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

128

Participants

Timeline

Start Date

April 30, 2024

Primary Completion Date

April 30, 2026

Study Completion Date

September 30, 2027

Conditions
TGCT
Interventions
DRUG

Emactuzumab

Emactuzumab administered once every 2 weeks (q2w)

DRUG

Placebo

Matching placebo administered once every 2 weeks (q2w)

Trial Locations (48)

112

Taipei Veterans General Hospital, Taipei

1200

Cliniques Universitaires Saint-Luc, Woluwe-Saint-Lambert

3010

Inselspital - Universitätsspital Bern, Bern

3080

Seoul National University Hospital, Seoul

4031

Universitäts Kinderspital Beider Basel (UKBB), Basel

8036

LKH-Universitätsklinikum Graz, Graz

8041

Hospital de La Santa Creu i Sant Pau, Barcelona

9000

UZ Gent - Department of Medical Oncology, Ghent

10002

National Taiwan University Hospital, Taipei

10060

Fondazione del Piemonte per l'Oncologia (IRCCS), Candiolo

20010

MedStar Washington Hospital Center, Georgetown

20133

Fondazione IRCCS Istituto Nazionale dei Tumori, Milan

27710

Duke Cancer Center, Durham

28040

Hospital Clinico San Carlos, Madrid

31059

Oncopole Claudius Regaud Oncologie Médicale, Toulouse

33000

Institut Bergonie - PPDS, Bordeaux

40136

IRCCS lstituto Ortopedico Rizzoli, Bologna

41013

Hospital Universitario Virgen del Rocio - PPDS, Seville

43201

The Ohio State University, Columbus

44115

Institut de Cancerologie de Ouest - Saint Herblain, Saint-Herblain

46026

Hospital Universitari i Politecnic La Fe de Valencia, Valencia

50009

Hospital Universitario Fundacion Jimenez Diaz, Zaragoza

Hospital Universitario Miguel Servet, Zaragoza

55455

University of Minnesota, Minneapolis

56124

Azienda Ospedaliero Universitaria Pisana - Stabilimento di Cisanello, Pisa

56126

Azienda Ospedaliero Universitaria Pisana - Stabilimento di Cisanello, Pisa

59000

UNICANCER - Centre Oscar Lambret, Lille

59100

Nuovo Ospedale di Prato, Prato

66210

University of Kansas Cancer Center (Overland Park) - USOR, Overland Park

69373

Centre Léon Bérard Centre Régional de Lutte Contre Le Cancer Rhône Alpes, Lyon

75014

AP-HP - Hôpital Cochin - Port-Royal, site Cochin, Paris

75248

Institut Curie - Hôpital de Paris, Paris

77030

MD Anderson Cancer Center, Houston

90067

Sarcoma Oncology Research Center, LLC, Los Angeles

90089

USC Norris Comprehensive Cancer Center, Los Angeles

90127

Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone, Palermo

90212

NextGen Oncology, Beverly Hills

97239

OHSU Knight Cancer Institute Hematology Oncology, Portland

T2N 4N1

Arthur J.E. Child Comprehensive Cancer Centre, Calgary

M5G 2M9

Princess Margaret Cancer Centre, Toronto

H1T 2M4

McGill University Health Centre (MUHC), Montreal

06189

Centre Antoine Lacassagne, Nice

00128

Fondazione Policlinico Universitario Campus Bio-Medico, Rome

2333 ZA

Leids Universitair Medisch Centrum, Leiden

222 42

Skanes Universitetssjukhus Lund, Lund

LS9 7TF

St James's University Hospital, Leeds

NW1 2BU

University College Hospital, London

OX3 7LD

Churchill Hospital, Cancer Haematology Center, Oxford

All Listed Sponsors
lead

SynOx Therapeutics Limited

INDUSTRY

NCT05417789 - Study of Emactuzumab for Tenosynovial Giant Cell Tumor (TGCT) | Biotech Hunter | Biotech Hunter